Angiotensin Converting Enzyme 1 (ACE1)
Angiotensin Conversion Enzyme 1 inhibitors (ACE-1 inhibitors), such as enalapril and ramipril, and angiotensin receptor antagonists (colloquially known as angiotensin blockers or ARBs), such as candesartan and valsartan, could be of use in the prevention and treatment of the symptoms of coronavirus SARS-CoV-2(also known as 2019-nCoV), the cause of the infection known as COVID 19 [30]. At the moment (as of 21 March 2020) three related trials are listed on the ICTRP website of the WHO, the International Clinical Trials Registry Portal, as being planned or under way in China. The first, entitled ”Clinical characteristics difference between patients with and without ACE1 treatment with 2019-nCoV infection in China” was published on 12 February and is stated to be recruiting; it is also listed on clinicaltrials.gov. The other two are not recruiting: ”Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treatment for COVID-19 patients” (registered on 21 February but identified as withdrawn on clinicaltrials.gov) and ”Clinical research on the effects of ACEIs / ARBs on novel coronavirus pneumonia (CoVID-19) infection” (registered on 2 March) [31].